TY - JOUR
T1 - Therapeutic and Vaccine Options for COVID-19
T2 - Status after Six Months of the Disease Outbreak
AU - Maciorowski, Dawid
AU - Ogaugwu, Christian
AU - Durvasula, Subba Rao
AU - Durvasula, Ravi
AU - Kunamneni, Adinarayana
N1 - Publisher Copyright:
© Society for Laboratory Automation and Screening 2020.
PY - 2021/3
Y1 - 2021/3
N2 - An outbreak of the coronavirus disease 2019 (COVID-19) caused by an infection of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, in December 2019. This new virus belongs to the group of enveloped RNA beta-coronaviruses. Symptoms may differ in various infected persons, but major presentations include dry cough, nasal congestion, shortness of breath, fever, and general malaise. The disease appears to be more severe in patients above the age of 60 years and those with underlying conditions such as diabetes, cancer, cardiovascular diseases, chronic respiratory disease, and hypertension. There is still no approved vaccine against COVID-19, but more than a hundred are at different stages of development. It is known that the development of new drugs takes a relatively long time, so several known and already-approved drugs are being repurposed for the treatment of this disease. In this review, we explore the therapeutic and vaccine options that are available for COVID-19 6 months after its outbreak. Most noteworthy among the therapeutic options are dexamethasone, remdesivir, Avigan (favipiravir) and convalescent plasma.
AB - An outbreak of the coronavirus disease 2019 (COVID-19) caused by an infection of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, in December 2019. This new virus belongs to the group of enveloped RNA beta-coronaviruses. Symptoms may differ in various infected persons, but major presentations include dry cough, nasal congestion, shortness of breath, fever, and general malaise. The disease appears to be more severe in patients above the age of 60 years and those with underlying conditions such as diabetes, cancer, cardiovascular diseases, chronic respiratory disease, and hypertension. There is still no approved vaccine against COVID-19, but more than a hundred are at different stages of development. It is known that the development of new drugs takes a relatively long time, so several known and already-approved drugs are being repurposed for the treatment of this disease. In this review, we explore the therapeutic and vaccine options that are available for COVID-19 6 months after its outbreak. Most noteworthy among the therapeutic options are dexamethasone, remdesivir, Avigan (favipiravir) and convalescent plasma.
KW - COVID-19
KW - SARS-CoV-2
KW - drug repurposing
KW - therapeutics
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85097596207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097596207&partnerID=8YFLogxK
U2 - 10.1177/2472555220979579
DO - 10.1177/2472555220979579
M3 - Review article
C2 - 33319627
AN - SCOPUS:85097596207
SN - 2472-5552
VL - 26
SP - 311
EP - 329
JO - SLAS Discovery
JF - SLAS Discovery
IS - 3
ER -